Rhenman & Partners Asset Management AB Has $2.45 Million Holdings in Janux Therapeutics, Inc. $JANX

Rhenman & Partners Asset Management AB increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 81.6% during the third quarter, HoldingsChannel.com reports. The firm owned 100,127 shares of the company’s stock after buying an additional 45,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Janux Therapeutics were worth $2,447,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Osaic Holdings Inc. boosted its stake in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after buying an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after acquiring an additional 820 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Janux Therapeutics by 185.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after acquiring an additional 4,982 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on JANX. Piper Sandler lowered their target price on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Bank of America decreased their price objective on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Wedbush reissued an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus cut their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $56.91.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 8,072 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer owned 284,982 shares of the company’s stock, valued at $3,912,802.86. This trade represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 1,879 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $25,798.67. Following the completion of the transaction, the insider owned 83,095 shares of the company’s stock, valued at $1,140,894.35. This trade represents a 2.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 19,033 shares of company stock valued at $261,323. Insiders own 8.10% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX opened at $13.84 on Friday. The company has a market cap of $841.89 million, a price-to-earnings ratio of -7.56 and a beta of 2.88. The stock has a fifty day moving average price of $13.68 and a two-hundred day moving average price of $20.32. Janux Therapeutics, Inc. has a 52-week low of $12.12 and a 52-week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Key Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term 2026 quarterly EPS estimates (Q1–Q4 2026) and improved its FY2026 loss forecast (from ($2.70) to ($2.40)), while maintaining a “Buy” rating and a $45 price target — a supportive analyst endorsement that can help underpin the stock. HC Wainwright raises near‑term estimates
• Neutral Sentiment: Major media/analyst roundups (reported by Globe and Mail) listed Janux among healthcare names receiving analyst commentary today — this amplifies visibility but is informational rather than a direct catalyst. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright trimmed several longer‑term EPS forecasts (FY2027–FY2029 and FY2028 notably worse vs prior estimates), increasing uncertainty about Janux’s multi‑year trajectory and dampening upside despite the high target — a factor that likely contributed to selling pressure. HC Wainwright trims long‑term estimates

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.